Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Severely Itching Dermatitis and Palmoplantar Keratoderma as First Manifestation of T-cell Prolympho-cytic Leukaemia.

Hofmann SC, Koutcher K, Fabri M, Wahnschaffe L, Herling M, Zilberman E.

Acta Derm Venereol. 2019 Aug 13. doi: 10.2340/00015555-3288. [Epub ahead of print] No abstract available.

2.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch I, Haferlach C, Kubicek S, Mayerhoefer M, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402. [Epub ahead of print]

PMID:
31292114
3.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986. [Epub ahead of print]

4.

Enantioselective Synthesis of 4-Methyl-3,4-dihydroisocoumarin via Asymmetric Hydroformylation of Styrene Derivatives.

Qu B, Tan R, Herling MR, Haddad N, Grinberg N, Kozlowski MC, Zhang X, Senanayake CH.

J Org Chem. 2019 Apr 19;84(8):4915-4920. doi: 10.1021/acs.joc.8b02813. Epub 2019 Mar 6.

PMID:
30779574
5.

The dawn of a new era in treating T-PLL.

Schrader A, Braun T, Herling M.

Oncotarget. 2019 Jan 18;10(6):626-628. doi: 10.18632/oncotarget.26595. eCollection 2019 Jan 18. No abstract available.

6.

Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases.

Kotrova M, Novakova M, Oberbeck S, Mayer P, Schrader A, Knecht H, Hrusak O, Herling M, Brüggemann M.

Cytometry A. 2018 Nov;93(11):1118-1124. doi: 10.1002/cyto.a.23604. Epub 2018 Nov 10.

PMID:
30414304
7.

Enantioselective Vanadium-Catalyzed Oxidative Coupling: Development and Mechanistic Insights.

Kang H, Herling MR, Niederer KA, Lee YE, Vasu Govardhana Reddy P, Dey S, Allen SE, Sung P, Hewitt K, Torruellas C, Kim GJ, Kozlowski MC.

J Org Chem. 2018 Dec 7;83(23):14362-14384. doi: 10.1021/acs.joc.8b02083. Epub 2018 Nov 14.

PMID:
30376626
8.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.

PMID:
30234404
9.

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT.

Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18.

10.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

11.

Nucleotide excision repair as a targetable vulnerability in leukemia.

Lohmann G, Schumacher B, Herling M.

Oncotarget. 2017 Dec 6;8(70):114420-114421. doi: 10.18632/oncotarget.22998. eCollection 2017 Dec 29. No abstract available.

12.

Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.

13.

Purely Physisorption-Based CO-Selective Gate-Opening in Microporous Organically Pillared Layered Silicates.

Herling MM, Rieß M, Sato H, Li L, Martin T, Kalo H, Matsuda R, Kitagawa S, Breu J.

Angew Chem Int Ed Engl. 2018 Jan 8;57(2):564-568. doi: 10.1002/anie.201710717. Epub 2017 Dec 8.

PMID:
29178514
14.

Asymmetric Oxidative Coupling of Phenols and Hydroxycarbazoles.

Kang H, Lee YE, Reddy PVG, Dey S, Allen SE, Niederer KA, Sung P, Hewitt K, Torruellas C, Herling MR, Kozlowski MC.

Org Lett. 2017 Oct 20;19(20):5505-5508. doi: 10.1021/acs.orglett.7b02552. Epub 2017 Oct 12.

15.

Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.

Tur MK, Daramola AK, Gattenlöhner S, Herling M, Chetty S, Barth S.

Biomedicines. 2017 Oct 4;5(4). pii: E59. doi: 10.3390/biomedicines5040059. Review.

16.

Determination of the Influence of the Antiphlogistic Ingredients Panthenol and Bisabolol on the SPF Value in vivo.

Werner M, Herling M, Garbe B, Theek C, Tronnier H, Heinrich U, Braun N.

Skin Pharmacol Physiol. 2017;30(6):284-291. doi: 10.1159/000480301. Epub 2017 Oct 4.

17.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
18.

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.

Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC.

Nat Commun. 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6.

19.

Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.

Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, Höller K, Sierra S, Knops E, Kaiser R, Scheid C, Di Cristanziano V.

Med Microbiol Immunol. 2017 Oct;206(5):355-362. doi: 10.1007/s00430-017-0511-4. Epub 2017 Jul 12.

PMID:
28702856
20.

Semi-automated cancer genome analysis using high-performance computing.

Crispatzu G, Kulkarni P, Toliat MR, Nürnberg P, Herling M, Herling CD, Frommolt P.

Hum Mutat. 2017 Oct;38(10):1325-1335. doi: 10.1002/humu.23275. Epub 2017 Jul 17.

PMID:
28598576
21.

Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other.

Rengstl B, Kim S, Döring C, Weiser C, Bein J, Bankov K, Herling M, Newrzela S, Hansmann ML, Hartmann S.

PLoS One. 2017 May 15;12(5):e0177378. doi: 10.1371/journal.pone.0177378. eCollection 2017.

22.

Dynamics of BKPyV reactivation and risk of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Höller K, Fabeni L, Herling M, Holtick U, Scheid C, Knops E, Lübke N, Kaiser R, Pfister H, Di Cristanziano V.

Eur J Haematol. 2017 Aug;99(2):133-140. doi: 10.1111/ejh.12895. Epub 2017 May 30.

PMID:
28401591
23.

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach.

Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, Herling M, Maciejewski J, Mustjoki S, Bortoluzzi S.

Leukemia. 2017 May;31(5):1243-1246. doi: 10.1038/leu.2017.49. Epub 2017 Feb 7. No abstract available.

24.

Sub-micron pore size tailoring for efficient chiral discrimination.

Herling MM, Lacher U, Rieß M, Seibt S, Schwedes M, Kalo H, Schobert R, Breu J.

Chem Commun (Camb). 2017 Jan 17;53(6):1072-1075. doi: 10.1039/c6cc09484h.

PMID:
28044170
25.

Constant Volume Gate-Opening by Freezing Rotational Dynamics in Microporous Organically Pillared Layered Silicates.

Bärwinkel K, Herling MM, Rieß M, Sato H, Li L, Avadhut YS, Kemnitzer TW, Kalo H, Senker J, Matsuda R, Kitagawa S, Breu J.

J Am Chem Soc. 2017 Jan 18;139(2):904-909. doi: 10.1021/jacs.6b11124. Epub 2017 Jan 3.

PMID:
27992224
26.

Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.

Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM.

Ann Hematol. 2017 Mar;96(3):479-487. doi: 10.1007/s00277-016-2887-4. Epub 2016 Dec 1.

PMID:
27909887
27.

Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells.

Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, von Strandmann EP.

Haematologica. 2017 Mar;102(3):e100-e103. doi: 10.3324/haematol.2016.153197. Epub 2016 Nov 17. No abstract available.

28.

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.

Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M.

Leukemia. 2017 May;31(5):1177-1186. doi: 10.1038/leu.2016.294. Epub 2016 Oct 24.

PMID:
27773933
29.

Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology<sup/>.

Herling M, Rengstl B, Scholtysik R, Hartmann S, Küppers R, Hansmann ML, Diebner HH, Roeder I, Abken H, Newrzela S, Kirberg J.

Leuk Lymphoma. 2017 Apr;58(4):788-796. doi: 10.1080/10428194.2016.1222381. Epub 2016 Sep 19.

PMID:
27643643
30.

Antigen-presenting human B cells are expanded in inflammatory conditions.

Shimabukuro-Vornhagen A, García-Márquez M, Fischer RN, Iltgen-Breburda J, Fiedler A, Wennhold K, Rappl G, Abken H, Lehmann C, Herling M, Wolf D, Fätkenheuer G, Rubbert-Roth A, Hallek M, Theurich S, von Bergwelt-Baildon M.

J Leukoc Biol. 2017 Feb;101(2):577-587. doi: 10.1189/jlb.5A0416-182R. Epub 2016 Aug 17.

PMID:
27534894
31.

Race or Resource? BMI, Race, and Other Social Factors as Risk Factors for Interlimb Differences among Overweight Breast Cancer Survivors with Lymphedema.

Dean LT, Kumar A, Kim T, Herling M, Brown JC, Zhang Z, Evangelisti M, Hackley R, Kim J, Cheville A, Troxel AB, Schwartz JS, Schmitz KH.

J Obes. 2016;2016:8241710. doi: 10.1155/2016/8241710. Epub 2016 Jun 28.

32.

General Solution for Stabilizing Triple Helical Collagen.

Zhang Y, Herling M, Chenoweth DM.

J Am Chem Soc. 2016 Aug 10;138(31):9751-4. doi: 10.1021/jacs.6b03823. Epub 2016 Jul 27.

PMID:
27410188
33.

Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor.

Aghajanian H, Cho YK, Manderfield LJ, Herling MR, Gupta M, Ho VC, Li L, Degenhardt K, Aharonov A, Tzahor E, Epstein JA.

Nat Commun. 2016 Jun 30;7:12038. doi: 10.1038/ncomms12038.

34.

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA.

Blood. 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25.

35.

CD1d-restricted peripheral T cell lymphoma in mice and humans.

Bachy E, Urb M, Chandra S, Robinot R, Bricard G, de Bernard S, Traverse-Glehen A, Gazzo S, Blond O, Khurana A, Baseggio L, Heavican T, Ffrench M, Crispatzu G, Mondière P, Schrader A, Taillardet M, Thaunat O, Martin N, Dalle S, Le Garff-Tavernier M, Salles G, Lachuer J, Hermine O, Asnafi V, Roussel M, Lamy T, Herling M, Iqbal J, Buffat L, Marche PN, Gaulard P, Kronenberg M, Defrance T, Genestier L.

J Exp Med. 2016 May 2;213(5):841-57. doi: 10.1084/jem.20150794. Epub 2016 Apr 11.

36.

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.

Leukemia. 2016 Jul;30(7):1520-30. doi: 10.1038/leu.2016.49. Epub 2016 Mar 8.

PMID:
27055871
37.

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.

Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V.

Leukemia. 2016 Aug;30(8):1763-6. doi: 10.1038/leu.2016.41. Epub 2016 Mar 4. No abstract available.

38.

A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells.

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M.

Mol Cancer Ther. 2016 May;15(5):971-84. doi: 10.1158/1535-7163.MCT-15-0685. Epub 2016 Jan 29.

39.

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.

Stiefelhagen M, Gigel C, Vasyutina E, Möllmann M, Breuer A, Mayer P, Dürig J, Herling M.

Leuk Lymphoma. 2016 Sep;57(9):2235-8. doi: 10.3109/10428194.2015.1135433. Epub 2016 Jan 12. No abstract available.

PMID:
26758550
40.

Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity.

Herling M, Schröder L, Awerkiew S, Chakupurakal G, Holtick U, Kaiser R, Pfister H, Scheid C, Di Cristanziano V.

J Clin Virol. 2016 Jan;74:57-60. doi: 10.1016/j.jcv.2015.11.033. Epub 2015 Nov 30.

PMID:
26672492
41.

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M.

Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.

42.

Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.

Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M.

Mol Cancer. 2015 Jun 4;14:114. doi: 10.1186/s12943-015-0378-1.

43.

Vitamin D controls apoptosis and proliferation of cutaneous T-cell lymphoma cells.

Mrotzek C, Felcht M, Sommer A, Schrader A, Klemke CD, Herling M, Schlaak M, Fabri M.

Exp Dermatol. 2015 Oct;24(10):798-800. doi: 10.1111/exd.12746. Epub 2015 May 22. No abstract available.

PMID:
25940772
44.

The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M.

Leukemia. 2015 Oct;29(10):2003-14. doi: 10.1038/leu.2015.114. Epub 2015 May 4.

PMID:
25936528
45.

Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL).

Dondorf S, Schrader A, Herling M.

J Biol Chem. 2015 Apr 17;290(16):10568-9. doi: 10.1074/jbc.L115.644641. No abstract available.

46.

Multilevel BCR signals toward CLL.

Herling M, Vasyutina E.

Blood. 2015 Mar 5;125(10):1510-2. doi: 10.1182/blood-2015-01-621227.

47.

Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?

Herling M.

Eur J Haematol. 2015 Mar;94(3):191-2. doi: 10.1111/ejh.12462. No abstract available.

PMID:
25712069
48.

AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.

Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, Hallek M, Herling M.

Curr Cancer Drug Targets. 2014;14(8):700-12.

PMID:
25348018
49.

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13.

50.

Models for mature T-cell lymphomas--a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts.

Warner K, Crispatzu G, Al-Ghaili N, Weit N, Florou V, You MJ, Newrzela S, Herling M.

Crit Rev Oncol Hematol. 2013 Dec;88(3):680-95. doi: 10.1016/j.critrevonc.2013.07.014. Epub 2013 Aug 21. Review.

PMID:
23972664

Supplemental Content

Loading ...
Support Center